Mylan Pharmaceuticals Inc.
https://www.mylan.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mylan Pharmaceuticals Inc.
Alembic Remains Upbeat Despite Rhizen Setback
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.
Setback For Alembic-backed Rhizen After Concerns Over PI3K Inhibitors
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has15-plus launches lined up.
Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
Excuses, Excuses: How ‘Delayed’ Confirmatory Trials Are Explained By FDA
US FDA currently reports about two dozen Accelerated Approval having ‘delays’ in the confirmatory trials. COVID is one factor in some – and the agency also appears to be clearing out some of the others.
Company Information
- Industry
- Pharmaceuticals